Olfax Medical is advancing OFX-001, a self-administered, direct-to-nerve therapeutic for trigeminal-mediated pain conditions — including cluster headache, migraine, post-traumatic headache, and trigeminal neuralgia — through clinical development toward commercialization.

We’re engaging with pharmaceutical and biotech partners who share our commitment to bringing better treatment options to patients with these conditions. We’re open to a range of partnership structures, including:

• Co-development
• Licensing
• Strategic transactions

If your organization is focused on headache, pain, or neurology therapeutics and interested in exploring a partnership, we’d welcome the conversation.

Press + Media

Follow this site to learn more about Olfax Medical’s progress, and explore our recent announcements. For additional media enquiries, please contact us at info@olfaxmedical.com